A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information
First Received Date ^†	November 2, 1999
Last Updated Date	October 1, 2007
Start Date ^†
Current Primary Outcome Measures ^†
Original Primary Outcome Measures ^†
Change History	Complete list of historical versions of study NCT00002300 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^†
Original Secondary Outcome Measures ^†

Descriptive Information
Brief Title ^†	A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition
Official Title ^†	Phase II-III Randomized Double-Blind Study Comparing Megestrol Acetate at 100, 400, and 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia
Brief Summary	To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To characterize dose response in relation to weight gain. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients with cachexia. To evaluate megestrol acetate's effect on immune function via skin test reactivity, T4/T8 ratio, and total lymphocytes.
Detailed Description
Study Phase	Phase II
Study Type ^†	Interventional
Study Design ^†	Treatment, Double-Blind
Condition ^†	Anorexia Cachexia HIV Infections
Intervention ^†	Drug: Megestrol acetate
Study Arms / Comparison Groups
Publications *	Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Anticancer Res. 1997 Jan-Feb;17(1B):657-62. Review.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^†	Completed
Enrollment ^†
Completion Date
Primary Completion Date
Eligibility Criteria ^†	Inclusion Criteria Patient must have: Confirmed diagnosis of AIDS (CDC definition). Documented weight loss or anorexia. Life expectancy = or > 20 weeks. The perception that the weight loss is a detriment to their well-being. Ability to provide informed consent, read and write English. Prior Medication: Allowed: Ganciclovir. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Dementia or evidence of mental incompetence which would preclude compliance with the protocol. Diarrhea defined as 5 or more watery stools per day for at least 7 days. Active uncontrolled systemic infections at the start of treatment. (Patients may not be entered for at least 2 weeks after acute infection.) Clinical or radiologic evidence of ascites or pleural effusions. Concurrent Medication: Excluded: Therapy designed to treat the underlying HIV infection or which may have a major impact on appetite and/or weight gain. Patients who have been started on zidovudine (AZT) within eight weeks. (Patients may have been previously treated with AZT and failed or may currently be receiving AZT for at least 8 weeks.) Patients with the following are excluded: Obstruction to food intake or impaired digestive/absorptive functions. Contraindications to high-dose megestrol acetate (poorly controlled hypertension or heart failure or deep vein thrombosis). Inability to consent or be available for close follow-up. Active systemic infections at the start of treatment. Patients may not be started on any therapy designed to treat the underlying HIV infection or which may have a major impact on appetite and/or weight gain. Clinical or radiologic evidence of ascites or pleural effusions. Patients may not be started on any therapy designed to treat the underlying HIV infection or which may have a major impact on appetite and/or weight gain. Patients who have been hospitalized or have suffered an exacerbation of their illness associated with weight loss within the past 2 weeks are excluded. Menstruating female patients are excluded. Prior Medication: Excluded: Corticosteroids. Anabolic steroids. Marijuana. Megestrol acetate. Patients who have been started on zidovudine (AZT) within 8 weeks. (Patients may have been previously treated with AZT and failed or may currently be receiving AZT for at least 8 weeks.) History of substance abuse and questionable current and future abstinence.
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States
Expanded Access Status

Administrative Information
NCT ID ^†	NCT00002300
Responsible Party
Secondary IDs ^††	MEG8807
Study Sponsor ^†	Bristol-Myers Squibb
Collaborators ^††
Investigators ^†
Information Provided By	Bristol-Myers Squibb
Verification Date	October 2007
^† Required WHO trial registration data element. ^†† WHO trial registration data element that is required only if it exists.